Xeris Biopharma Quarterly Income Statement
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xeris Biopharma revenue and earnings
In the quarter ended Jun 30, 2026, Xeris Biopharma generated $92.1 million in revenue, up 28.7% from the same quarter a year earlier. Xeris Biopharma reported a net loss of $31.1 million, compared with a loss of $1.9 million a year earlier. Gross margin was 86.4% (up from 83.4%) and operating margin 5.6%.
Diluted earnings per share came in at -$0.18.
Summary generated from market data by MetaCap's automated system. Methodology
Xeris Biopharma income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 92.10M | 83.13M | 85.81M | 74.38M | 71.54M | 60.12M | 60.10M | 54.27M | 48.06M | 40.64M | 44.39M | 48.32M |
| Revenue growth (YoY) | +28.74% | +38.27% | +42.78% | +37.06% | +48.84% | +47.94% | +35.39% | +12.31% | +26.46% | +22.42% | +33.93% | +62.56% |
| Cost of Revenue | 12.51M | 10.57M | 10.95M | 11.00M | 11.90M | 8.73M | 9.48M | 13.59M | 7.79M | 5.97M | 7.57M | 8.20M |
| Gross Profit | 79.59M | 72.55M | 74.86M | 63.38M | 59.64M | 51.39M | 50.62M | 40.67M | 40.27M | 34.67M | 36.82M | 40.12M |
| Operating Expenses | 74.42M | 64.64M | 58.09M | 56.65M | 55.16M | 54.48M | 48.94M | 53.57M | 48.46M | 48.91M | 46.66M | 45.03M |
| Research & Development | 10.67M | 8.78M | 7.87M | 7.48M | 8.05M | 7.75M | 6.09M | 5.89M | 5.76M | 7.82M | 6.38M | 5.03M |
| Selling, General & Admin | 61.03M | 53.14M | 47.50M | 46.46M | 44.39M | 44.02M | 40.14M | 44.97M | 39.99M | 38.38M | 37.57M | 37.29M |
| Operating Income | 5.17M | 7.92M | 16.77M | 6.73M | 4.48M | -3.09M | 1.68M | -12.89M | -8.19M | -14.24M | -9.84M | -4.91M |
| Interest Expense | 6.95M | 6.88M | 7.15M | 7.27M | 7.36M | 7.30M | 7.70M | 7.79M | 7.96M | 7.03M | 7.02M | 6.85M |
| Other Income (Expense) | -36.27M | -5.68M | -5.69M | -6.11M | -6.41M | -6.13M | -6.79M | -6.17M | -6.07M | -4.43M | -3.79M | -7.61M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -3.32M | 749.00K | 307.00K | -236.00K | -338.00K |
| Net Income | -31.10M | 2.23M | 11.08M | 621.00K | -1.93M | -9.22M | -5.11M | -15.74M | -15.01M | -18.98M | -13.39M | -12.19M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.18 | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 | -0.02 | -0.11 | -0.10 | -0.14 | -0.10 | -0.09 |
| EPS (Diluted) | -0.18 | 0.01 | 0.07 | 0.00 | -0.01 | -0.06 | -0.02 | -0.11 | -0.10 | -0.14 | -0.10 | -0.09 |
| Shares Outstanding (Basic) | 172.82M | 170.52M | — | 163.65M | 159.46M | 152.45M | — | 148.99M | 148.35M | 140.51M | — | 138.06M |
| Shares Outstanding (Diluted) | 172.82M | 177.63M | — | 177.62M | 159.46M | 152.45M | — | 148.99M | 148.35M | 140.51M | — | 138.06M |
| EBITDA | 5.50M | 8.25M | 17.11M | 7.07M | 4.81M | -2.77M | 1.99M | -12.59M | -7.91M | -13.92M | -9.49M | -4.52M |
| Gross Margin | 86.41% | 87.28% | 87.24% | 85.22% | 83.37% | 85.48% | 84.23% | 74.95% | 83.79% | 85.31% | 82.95% | 83.03% |
| Operating Margin | 5.62% | 9.52% | 19.55% | 9.05% | 6.27% | -5.14% | 2.79% | -23.76% | -17.03% | -35.05% | -22.17% | -10.17% |
| Net Margin | -33.77% | 2.69% | 12.91% | 83.00% | -2.70% | -15.34% | -8.51% | -29.00% | -31.22% | -46.71% | -30.16% | -25.23% |
This table shows 12 quarterly periods of Xeris Biopharma's income statement, from Q2 2026 back to Q3 2023, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow XERS's reporting calendar. What is a income statement?